In some embodiments, the present invention relates to novel small molecule inhibitors that block the CXCR4-SDF-1 signaling pathway by directly inhibiting the members of the Tec family of kinases, namely Broncs tyrosine kinese (BTK) and their use in treating disorders in which pathogenesis is mediated by the CXCR4-SDF-1 signaling pathway.